Synthesis, Antifungal Activity, and Molecular Simulation of Vanillin-Based 1,3,4-Oxadiazole-Thioether Derivatives as Potential Succinate Dehydrogenase Inhibitors
Molecules · 06.11.2026 · 31 (21) · 4004
DOI: 10.3390/molecules31214004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 06.11.2026. Verfasst von Wei-Wei Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Guangxi University, Nanning 530004, China. Hauptthemen laut MEDLINE: Succinate Dehydrogenase, Oxadiazoles, Antifungal Agents, Benzaldehydes. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
To explore potent natural product-based antifungal agents, thirty-two new vanillin-based 1,3,4-oxadiazole-thioether compounds were rationally designed and synthesized in this study. Their chemical structures were comprehensively confirmed by FT-IR, 1H NMR, 13C NMR, and HRMS. The in vitro antifungal activity of the target compounds against eight phytopathogenic fungi was preliminarily assayed using the agar dilution method, with the commercial fungicide boscalid, a succinate dehydrogenase inhibitor (SDHI), as the positive control. Results indicated that compounds 6n, 6o, and 6r displayed significant inhibitory activity against Physalospora piricola (P. p.). Further EC50 tests revealed that these three compounds were all more effective than boscalid. Subsequently, to explore the relationship between structures of the target compounds and their antifungal activity against P. p., a valid and reliable three-dimensional quantitative structure–activity relationship (3D-QSAR) model was established via the CoMFA method. Also, the density functional theory (DFT) calculations, including ESP and FMOs, were calculated to further elucidate the structure–activity relationship. To investigate the action mechanism between the target compounds and the potential biological target succinate dehydrogenase (SDH), the inhibitory activity of compounds 6n, 6o, and 6r against SDH was assessed in this work. The results displayed that their SDH inhibitory activities were superior to that of the positive control, boscalid. Molecular docking simulations revealed that compound 6n exhibited a binding mode similar to that of boscalid. Therefore, the target compound 6n might exert excellent antifungal activity through inhibition of SDH. Compound 6n deserves in-depth research as a lead compound for developing novel fungicides.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Guangxi University, Nanning 530004, China.
- Guangxi Key Laboratory for Pharmaceutical Molecular Discovery and Druggability Optimization, School of Pharmacy, Guilin Medical University, Guilin 541199, China.
ORCID-Profile: Yu-Cheng Cui
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, W. W., Wei, J. W., Ye, Z. R., Li, Y. H., Cui, Y. C., Lin, G. S., Duan, W. G., & Ma, X. L. (2026). Synthesis, Antifungal Activity, and Molecular Simulation of Vanillin-Based 1,3,4-Oxadiazole-Thioether Derivatives as Potential Succinate Dehydrogenase Inhibitors. Molecules, 31(21), 4004. https://doi.org/10.3390/molecules31214004
Vancouver
Liu WW, Wei JW, Ye ZR, Li YH, Cui YC, Lin GS, et al. Synthesis, Antifungal Activity, and Molecular Simulation of Vanillin-Based 1,3,4-Oxadiazole-Thioether Derivatives as Potential Succinate Dehydrogenase Inhibitors. Molecules. 2026;31(21):4004. doi:10.3390/molecules31214004
BibTeX
@article{Liu2026,
author = {Liu, Wei-Wei and Wei, Jing-Wen and Ye, Zi-Ruo and Li, Ying-Hao and Cui, Yu-Cheng and Lin, Gui-Shan and Duan, Wen-Gui and Ma, Xian-Li},
title = {Synthesis, Antifungal Activity, and Molecular Simulation of Vanillin-Based 1,3,4-Oxadiazole-Thioether Derivatives as Potential Succinate Dehydrogenase Inhibitors},
journal = {Molecules},
year = {2026},
volume = {31},
number = {21},
pages = {4004},
doi = {10.3390/molecules31214004}
}
EUVIMED